Should medicare adopt the veterans health administration formulary?

Health Economics

Volumn 21, Issue 5, 2012, Pages 485-495

  Frakt, Austin B ^a,b   Pizer, Steven D ^a,b   Feldman, Roger ^c  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Demand elasticity; Formulary; Medicare; Prescription drugs; Welfare analysis

Indexed keywords

GENERIC DRUG;

ARTICLE; CONCEPTUAL FRAMEWORK; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG FORMULATION; DRUG MARKETING; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HUMAN; MEDICAID; MEDICARE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; SAMPLE SIZE; SENSITIVITY ANALYSIS; VETERAN;

COST SAVINGS; FORMULARIES AS TOPIC; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MEDICARE PART D; MODELS, ECONOMETRIC; PRESCRIPTION DRUGS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84859428565     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1733     Document Type: Article

References (46)

1. Atherly A, Dowd B, Feldman R. 2004. The effect of benefits, premiums, and health risk on health plan choice in the medicare program. Health Services Research 39(4): 847-864. (Pubitemid 38924682)
2. Berry S. 1994. Estimating discrete-choice models of product differentiation. The RAND Journal of Health Economics 25(2): 242-262. Summer.
3. Berry S, Levinsohn J, Pakes A. 1995. Automobile prices in market equilibrium. Econometrica 63(4): 841-890.
4. Bresnahan T. 1987. Competition and collusion in the American automobile oligopoly: the 1955 price war. Journal of Industrial Economics 35: 457-482.
5. Bresnahan T, Stern S, Trajtenberg M. 1997. Market segmentation and the sources of rents from innovation: personal computers in the late 1980s. RAND Journal of Economics 28: S17-S44.
6. Cawley J, Chernew M, McLaughlin C. 2005. HMO participation in medicare1choice. Journal of Economics and Management Strategy 14(3): 543-574.
7. Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services (CMS). 2005a. Medicare modernization act final guidelines - formularies: guidelines for reviewing prescription drug plan formularies and procedures.
8. Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services (CMS). 2005b. Why is CMS requiring 'all or substantially all' of the drugs in the antidepressant, antipsychotic, anticonvulsant, anticancer, immunosuppressant, and HIV/AIDS categories?
9. Chester B, Valentino M. 2007. Access to affordable medications. American Journal of Public Health 97: 2129-2131.
10. Congressional Budget Office. 2007. Analysis of H.R.4. (Available from: www.cbo.gov/ftpdocs/77xx/doc7722/hr4.pdf.)
11. Cubanski J, Neuman P. 2007. Status report on medicare part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Affairs Web Exclusives W1-W12; DOI: 10.1377/hlthaff.26.1.w1.
12. Donohue J, Huskamp H, Zuvekas S. 2009. Dual eligibles with mental disorders and medicare Part D: how are they faring? Health Affairs 28(3): 746-759.
13. Dowd B, Feldman R, Coulam R. 2003. The effect of health plan characteristics on medicare1choice enrollment. Health Services Research 38: 1, Part I, February.
14. Families USA. 2005. Falling short: medicare prescription drug plans offer meager savings, December. (Available from: www.familiesusa.org/assets/pdfs/PDP- vs-VA-prices-special-report.pdf.)
15. Families USA. 2007. No bargain: medicare drug plans deliver high prices, January. (Available from: www.familiesusa.org/assets/pdfs/no-bargain-medicare- drug.pdf.)
16. Frakt A, Pizer S. 2006. A first look at the new medicare prescription drug plans. Health Affairs Web Exclusive 25(4): W252-W261. (Pubitemid 44188209)
17. Frakt AB, Pizer SD. 2010. Beneficiary price sensitivity in the medicare prescription drug plan market. Health Economics 19(1): 88-100.
18. Frakt AB, Pizer SD, Hendricks AM. 2008. Controlling prescription drug costs: regulation and the role of interest groups in medicare and the Veterans Health Administration. Journal of Health Politics, Policy and Law 33(6): 1079-1106.
19. Gellad W, Schneeweiss S, Brawarsky P, Lipsitz S, Hass J. 2008. What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings. Journal of General Internal Medicine 23(9): 1435-1440.
20. Hausman J, McFadden D. 1984. Specification tests for the multinomial logit model. Econometrica 52(5): 1219-1240.
21. Hausman J, Leonard G, Zona JD. 1994. Competitive analysis with differentiated products. Annales d'Economie et de Statistique 34: 159-180.
22. Hoadley J et al. 2007. Medicare Part D 2008 data spotlight: premiums. The Henry J. Kaiser Family Foundation, November.
23. Hoadley J, Hargrave E, Cubanski J. 2008. Medicare Part D 2008 data spotlight: low-income subsidy plan availability. The Henry J. Kaiser Family Foundation, April.
24. Huskamp H et al. 2003. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for medicare? Health Affairs 22: 149-158. (Pubitemid 41388751)
25. Lichtenberg F. 2005. Older drugs, shorter lives? An examination of the health effects of the veterans health administration formulary, No. 2, Center for Medical Progress, The Manhattan Institute, October.
26. Lucarelli C, Prince J, Simon K. 2008. Measuring welfare and the effects of regulation in a government-created market: the case of medicare Part D plans. Working Paper 14296, National Bureau of Economics Research, September.
27. McAdams D, Schwarz M. 2007. Perverse incentives in the medicare prescription drug benefit. Inquiry 44: 157-166. (Pubitemid 47326681)
28. Montgomery L, Lee C. 2006. Success of drug plan challenges democrats. Washington Post, November 26.
29. Neuman P, Strollo M, Guterman S, Rogers W, Li A, Mae A, Rodday C, Safran D. 2007. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Affairs 26(5): w630-w643.
30. Nevo A. 2000. A Practitioner's guide to estimation of random-coefficients logit models of demand. Journal of Economics and Management Strategy 9(4): 513-548.
31. Nevo A. 2001. Measuring market power in the ready-to-eat cereal industry. Econometrica 69(2): 307-342. (Pubitemid 33645351)
32. Nugent G, Hendricks A, Nugent L, Render M. 2004. Value for taxpayers' dollars: what VA care would cost at medicare prices. Medical Care Research and Review 61: 495-508. (Pubitemid 39491931)
33. Oehlert G. 1992. A note on the delta method. American Statistician 46: 27-29.
34. Outterson K, Kesselheim A. 2009. How medicare could get better prices on prescription drugs. Health Affairs 28: w832-w841.
35. Pizer S, Frakt A, Feldman R. 2008. Predicting risk selection following major changes in Medicare. Health Economics 17(4).
36. Pizer S, Frakt A, Feldman R. 2009. Nothing for something: estimating cost and value for beneficiaries from recent medicare spending increases on HMO payments and drug benefits. International Journal of Health Care Finance and Economics 9: 59-81.
37. Shearer G. 2007. Confusing inequitable medicare prescription drug benefit. Journal of General Internal Medicine 22: 286-288. (Pubitemid 47308824)
38. Sikora P, Schiavone H. 2006. Not low enough: medicare part D 'donut hole' prices compared with retail and VA prices. Consumers Union, October.
39. Small K, Rosen H. 1981. Applied welfare economics with discrete choice models. Econometrica 49(1): 105-130.
40. The Galen Institute. 2007. The facts: medicare part D and prescription drug prices, January 9. (Available from: www.galen.org/pdrugs.asp?docID=958).
41. Tirole J. 1995. The Theory of Industrial Organization. MIT Press: Cambridge, MA.
42. Town R, Liu S. 2003. The welfare impact of medicare HMOs. RAND Journal of Economics 34(4): 719-736. (Pubitemid 38284416)
43. Trajtenberg M. 1989. The welfare analysis of product innovations, with an application to computed tomography scanners. Journal of Political Economy 97(2): 444-479.
44. US Department of Health and Human Services. 2009. Medicare program: medicare advantage and prescription drug program MIPPA drug formulary and protected class policies. Federal Register 74(11): 2881-2888.
45. United States Government Accountability Office. 2005. Mail order pharmacies: DOD's use of VA's mail pharmacy could produce savings and other benefits. GAO-05-555, Washington, DC, June.
46. Yong J. 2007. Republicans criticize VA drug benefits. The Hill, Washington, DC, January 17.